The U.S. government is piloting a program that uses artificial intelligence to make insurance-coverage decisions, a move that promises to streamline a notoriously cumbersome process but also raises concerns about potential misapplications and exacerbating existing inequities in healthcare access. This initiative, championed by the Trump administration, seeks to leverage AI’s analytical power to reduce unnecessary medical spending and administrative burdens. However, the integration of AI into healthcare prior authorization—the system requiring physicians to obtain insurer approval before providing certain treatments or services—is met with both hope and significant apprehension from medical professionals and patient advocates alike.
The Thorny Landscape of Prior Authorization
For millions of Americans, the journey to receiving recommended medical care is fraught with delays and denials stemming from the prior authorization process. Physicians and patients frequently recount harrowing experiences of navigating a labyrinthine system designed to curb healthcare costs by scrutinizing the necessity and appropriateness of medical interventions. While proponents argue that prior authorization acts as a crucial check against overuse and unwarranted expenses, its implementation often leads to substantial delays, causing patients to abandon or postpone essential treatments. These delays can have profound consequences, particularly for individuals with chronic conditions or those requiring urgent care, potentially leading to worsened health outcomes and increased healthcare costs down the line due to delayed intervention.
The American Medical Association (AMA) has consistently highlighted physicians’ concerns regarding the impact of prior authorization on patient care. A significant majority of doctors report that this process contributes to care delays, forcing patients to wait for insurance companies to verify eligibility and medical necessity. The appeals process, while available, adds further layers of time and complexity, often proving to be a formidable hurdle for already beleaguered patients. The sheer volume of these requests is staggering; in Medicare Advantage plans alone, insurers issue millions of full or partial claim denials annually based on prior authorization. Federal reports have, at times, raised alarms about plans denying requests for essential services like skilled nursing and rehabilitation admissions, underscoring the potential for the system to create obstacles to medically appropriate care.
AI Enters the Arena: A Promise of Efficiency
In this challenging environment, artificial intelligence emerges as a potential solution. AI’s capacity to process vast datasets rapidly and identify patterns offers the theoretical promise of expediting approvals for clearly justifiable claims, thereby shortening the agonizing wait times patients currently endure. The notion is that AI can sift through clinical guidelines, patient records, and treatment protocols with unparalleled speed, flagging straightforward cases for quick approval and flagging complex ones for human review. This could theoretically free up valuable clinician time currently spent on administrative tasks, allowing them to focus more on direct patient care.
The Trump administration’s embrace of AI in this domain is exemplified by the WISeR (Wasteful and Inappropriate Service Reduction) Model, a demonstration project initiated by the Centers for Medicare and Medicaid Services (CMS). Launched in six states, WISeR aims to leverage AI, including machine learning, in conjunction with human clinical review, to identify and reduce waste, fraud, and abuse within original Medicare. The project targets specific services deemed vulnerable to overuse, such as certain skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy for osteoarthritis. This marks a significant shift, as prior authorization has historically been more prevalent in Medicare Advantage than in original Medicare. The stated goal of WISeR is to "ensure timely and appropriate Medicare payment for select items and services."
Growing Pains and Persistent Concerns
Despite the optimistic outlook from proponents, the integration of AI into prior authorization is not without its critics. A significant concern is the potential for AI to exacerbate wrongful denials. A 2025 survey by the AMA revealed that 61 percent of physicians worry that AI will lead to an increase in denials of treatments they deem medically necessary. This apprehension stems from the inherent complexities of medical necessity, which often involves nuanced clinical judgment that may not be fully captured by algorithms. The risk is that AI, in its pursuit of efficiency and cost reduction, might misinterpret or oversimplify complex clinical situations, leading to unfair denials.
The AMA advocates for greater transparency in AI algorithms used for prior authorization and insists that insurers provide detailed clinical reasoning to justify any denial of coverage. This call for transparency is echoed by health policy analysts like Camm Epstein, who stated, "AI should be used to make appropriate care easier to approve, not necessary care easier to deny." This sentiment encapsulates the core tension: ensuring AI serves as a tool for equitable access rather than a gatekeeper that further restricts it.
The structure of some AI-driven prior authorization programs also raises ethical questions. In the WISeR model, participating vendors are compensated based on "averted expenditures," meaning they earn a share of the costs saved by rejecting care requests. This financial incentive structure has ignited long-standing concerns about profit motives driving decisions to deny patients medically necessary care. Several lawmakers have introduced resolutions and amendments aimed at blocking funding for the WISeR model, citing threats to patient access and potential conflicts of interest.
A Dual Approach: Streamlining and Regulating
Interestingly, the Trump administration appears to be pursuing a dual strategy regarding prior authorization. While expanding AI’s role in original Medicare through initiatives like WISeR, CMS Administrator Mehmet Oz has simultaneously warned private insurers, including those in Medicare Advantage, to ease the burden of prior authorization. Oz has indicated that if the industry does not voluntarily streamline its processes, the federal government will impose stricter regulations. This message was delivered directly to insurance company executives, underscoring the administration’s intent to exert pressure for reform.
In response to these pressures, the health insurance industry has released data suggesting a reduction in prior authorization requests. Between June 2025 and April 2026, requests reportedly declined by 11 percent. Insurers have also pledged greater transparency regarding the clinical reasoning behind prior authorization decisions and have agreed that AI or algorithms alone will not be used to deny requests involving medical necessity or clinical considerations. These commitments aim to alleviate concerns about a lack of human oversight in AI-driven decisions.
However, the ultimate impact of these industry promises remains to be seen. While the reduction in prior authorization requests is a positive development, it is unclear whether the denial rate has also decreased. Critics like Jared Dashevsky, founder of Healthcare Huddle, argue that the current trajectory represents an "arms race to deny faster and appeal faster," rather than a genuine improvement in system efficiency or patient access. He contends that AI is being used to automate a fundamentally flawed system, rather than to create a truly equitable and efficient one.
The Path Forward: Balancing Innovation and Patient Welfare
The debate surrounding AI in prior authorization highlights a critical juncture in healthcare policy. The potential for AI to alleviate the administrative burdens and delays associated with prior authorization is significant. By automating routine checks and providing rapid approvals for straightforward cases, AI could allow healthcare providers to dedicate more time to patient care and reduce the frustration experienced by individuals seeking medical treatment.
However, the risks associated with the deployment of AI in this sensitive area are equally substantial. Concerns about algorithmic bias, the potential for increased wrongful denials, and the inherent limitations of technology in capturing the nuances of medical necessity cannot be ignored. The financial incentives embedded in some AI programs also warrant careful scrutiny to ensure that cost-saving measures do not come at the expense of patient well-being.
As the WISeR model and other AI-driven initiatives continue to evolve, ongoing evaluation and robust oversight will be crucial. A balance must be struck between harnessing the innovative potential of AI and safeguarding patient access to timely and appropriate medical care. This will likely require a multi-pronged approach involving clear regulatory guidelines, increased transparency from insurers, continued advocacy from medical professionals and patient groups, and a commitment from all stakeholders to prioritize patient welfare above all else. The success of AI in revolutionizing prior authorization will ultimately be measured not by the speed of approvals or the reduction in expenditures, but by its tangible impact on improving health outcomes and ensuring equitable access to care for all Americans.
